Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BLCO NASDAQ:LQDA NASDAQ:NVCR NYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCOBausch + Lomb$16.16-0.3%$16.20$10.99▼$18.92$5.76B0.59430,157 shs455,591 shsLQDALiquidia$61.97+0.3%$41.15$11.85▼$62.30$5.51B0.411.71 million shs1.20 million shsNVCRNovoCure$17.90+0.8%$13.16$9.82▼$20.06$2.07B0.91.80 million shs1.13 million shsSTVNStevanato Group€17.82+0.4%€15.57€12.89▼€28.00€5.40B0.75644,915 shs193,685 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCOBausch + Lomb-0.10%-0.25%-3.37%-8.35%+38.10%LQDALiquidia+2.98%+7.26%+64.02%+76.23%+262.93%NVCRNovoCure+4.35%-1.93%+40.09%+55.84%-2.47%STVNStevanato Group+1.58%+0.98%+11.42%+8.96%-27.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCOBausch + Lomb$16.16-0.3%$16.20$10.99▼$18.92$5.76B0.59430,157 shs455,591 shsLQDALiquidia$61.97+0.3%$41.15$11.85▼$62.30$5.51B0.411.71 million shs1.20 million shsNVCRNovoCure$17.90+0.8%$13.16$9.82▼$20.06$2.07B0.91.80 million shs1.13 million shsSTVNStevanato Group€17.82+0.4%€15.57€12.89▼€28.00€5.40B0.75644,915 shs193,685 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCOBausch + Lomb-0.10%-0.25%-3.37%-8.35%+38.10%LQDALiquidia+2.98%+7.26%+64.02%+76.23%+262.93%NVCRNovoCure+4.35%-1.93%+40.09%+55.84%-2.47%STVNStevanato Group+1.58%+0.98%+11.42%+8.96%-27.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCOBausch + Lomb 2.21Hold$18.0811.91% UpsideLQDALiquidia 2.92Moderate Buy$49.33-20.48% DownsideNVCRNovoCure 2.38Hold$27.2952.32% UpsideSTVNStevanato Group 2.40HoldN/AN/ACurrent Analyst Ratings BreakdownLatest NVCR, BLCO, STVN, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $67.005/12/2026LQDALiquidia Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$51.00 ➝ $62.005/11/2026LQDALiquidia Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/11/2026LQDALiquidia Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $70.005/11/2026LQDALiquidia BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $59.005/5/2026LQDALiquidia Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026NVCRNovoCure Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$13.50 ➝ $17.005/1/2026NVCRNovoCure EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/30/2026BLCOBausch + Lomb Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.004/21/2026LQDALiquidia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NVCRNovoCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCOBausch + Lomb$5.21B1.11$1.66 per share9.71$18.09 per share0.89LQDALiquidia$158.32M34.85N/AN/A$1.22 per share50.85NVCRNovoCure$655.35M3.17N/AN/A$2.86 per share6.26STVNStevanato Group€1.34B4.02€0.91 per share19.65€5.92 per share3.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCOBausch + Lomb-$360M-$0.62N/A14.960.50-4.21%3.60%1.69%7/29/2026 (Estimated)LQDALiquidia-$68.92M$0.14443.1512.90N/A7.74%46.82%7.06%N/ANVCRNovoCure-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)STVNStevanato Group€158.21M€0.5930.2122.281.6011.76%10.27%6.08%N/ALatest NVCR, BLCO, STVN, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LQDALiquidia$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million5/8/2026Q1 2026STVNStevanato Group€0.12€0.11-€0.01€0.10N/A€273.57 million4/30/2026Q1 2026NVCRNovoCure-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million4/29/2026Q1 2026BLCOBausch + Lomb$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion3/18/2026Q4 2025LQDALiquidia$0.01$0.15+$0.14N/AN/AN/A3/5/2026Q4 2025LQDALiquidia$0.08$0.15+$0.07$0.15$87.49 million$92.02 million2/26/2026Q4 2025NVCRNovoCure-$0.41-$0.22+$0.19-$0.22$174.40 million$174.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLCOBausch + LombN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCOBausch + Lomb0.781.530.99LQDALiquidia1.182.222.03NVCRNovoCure0.712.902.70STVNStevanato Group0.211.631.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCOBausch + Lomb11.07%LQDALiquidia64.54%NVCRNovoCure84.61%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipBLCOBausch + Lomb1.45%LQDALiquidia25.60%NVCRNovoCure5.52%STVNStevanato Group0.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLCOBausch + Lomb13,000356.57 million351.40 millionOptionableLQDALiquidia5088.93 million66.16 millionOptionableNVCRNovoCure1,605115.82 million109.43 millionOptionableSTVNStevanato Group6,010302.84 million300.72 millionOptionableNVCR, BLCO, STVN, and LQDA HeadlinesRecent News About These CompaniesStevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comStevanato Group SpA (STVN)May 10, 2026 | investing.comStevanato Group Margin Momentum Draws Fresh Market AttentionMay 10, 2026 | kalkinemedia.comKEarnings Beat: Stevanato Group S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 9, 2026 | finance.yahoo.comStevanato Group (NYSE:STVN) Issues Earnings Results, Misses Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comA Look At Stevanato Group’s (NYSE:STVN) Valuation After Its Recent Share Price ReboundMay 7, 2026 | finance.yahoo.comStevanato maintains 2026 guidance of €1.260B-€1.290B revenue as it targets RTU cartridge production in early 2027May 7, 2026 | msn.comStevanato Group Files Form 6-K Detailing Q1 2026 Results PresentationMay 7, 2026 | tipranks.comStevanato Group S.p.A. (STVN) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comStevanato Group (STVN) Q1 Earnings and Revenues Beat EstimatesMay 7, 2026 | zacks.comStevanato Group (NYSE:STVN) Releases FY 2026 Earnings GuidanceMay 7, 2026 | marketbeat.comStevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026May 7, 2026 | businesswire.comStevanato Group to Participate in Three Upcoming Investor ConferencesMay 4, 2026 | businesswire.comStevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of "Hold" by BrokeragesMay 4, 2026 | marketbeat.comJennison Associates LLC Buys 213,602 Shares of Stevanato Group S.p.A. $STVNMay 2, 2026 | marketbeat.comStevanato Group S.p.A. $STVN Shares Sold by Conestoga Capital Advisors LLCMay 1, 2026 | marketbeat.comStevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings GrowthApril 30, 2026 | zacks.comStevanato Group (NYSE:STVN) Volume Surge Sparks Market FocusApril 29, 2026 | kalkinemedia.comKStevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume - Should You Buy?April 29, 2026 | marketbeat.comHere’s Why Stevanato Group Spa (STVN) Declined in Q1April 28, 2026 | finance.yahoo.comStevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCR, BLCO, STVN, and LQDA Company DescriptionsBausch + Lomb NYSE:BLCO$16.16 -0.04 (-0.25%) Closing price 03:59 PM EasternExtended Trading$16.15 -0.01 (-0.06%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.Liquidia NASDAQ:LQDA$61.97 +0.20 (+0.32%) Closing price 04:00 PM EasternExtended Trading$62.15 +0.18 (+0.29%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.NovoCure NASDAQ:NVCR$17.90 +0.15 (+0.85%) Closing price 04:00 PM EasternExtended Trading$17.99 +0.09 (+0.50%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Stevanato Group NYSE:STVN€17.82 +0.07 (+0.40%) Closing price 03:59 PM EasternExtended Trading€17.86 +0.04 (+0.25%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
